JP5986575B2 - 精神病状態の制御および特徴付け - Google Patents

精神病状態の制御および特徴付け Download PDF

Info

Publication number
JP5986575B2
JP5986575B2 JP2013537878A JP2013537878A JP5986575B2 JP 5986575 B2 JP5986575 B2 JP 5986575B2 JP 2013537878 A JP2013537878 A JP 2013537878A JP 2013537878 A JP2013537878 A JP 2013537878A JP 5986575 B2 JP5986575 B2 JP 5986575B2
Authority
JP
Japan
Prior art keywords
light
opsin
amino acid
acid sequence
depolarization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013537878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544091A (ja
JP2013544091A5 (enExample
Inventor
ダイスロス，カール
ソハール，ヴィカス
ギュナイドゥン，リサ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2013544091A publication Critical patent/JP2013544091A/ja
Publication of JP2013544091A5 publication Critical patent/JP2013544091A5/ja
Application granted granted Critical
Publication of JP5986575B2 publication Critical patent/JP5986575B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0618—Psychological treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
JP2013537878A 2010-11-05 2011-11-04 精神病状態の制御および特徴付け Expired - Fee Related JP5986575B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41072010P 2010-11-05 2010-11-05
US41072510P 2010-11-05 2010-11-05
US61/410,720 2010-11-05
US61/410,725 2010-11-05
PCT/US2011/059383 WO2012061741A2 (en) 2010-11-05 2011-11-04 Control and characterization of psychotic states

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016155068A Division JP2017029148A (ja) 2010-11-05 2016-08-05 精神病状態の制御および特徴付け

Publications (3)

Publication Number Publication Date
JP2013544091A JP2013544091A (ja) 2013-12-12
JP2013544091A5 JP2013544091A5 (enExample) 2014-12-18
JP5986575B2 true JP5986575B2 (ja) 2016-09-06

Family

ID=46025139

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013537878A Expired - Fee Related JP5986575B2 (ja) 2010-11-05 2011-11-04 精神病状態の制御および特徴付け
JP2016155068A Pending JP2017029148A (ja) 2010-11-05 2016-08-05 精神病状態の制御および特徴付け

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016155068A Pending JP2017029148A (ja) 2010-11-05 2016-08-05 精神病状態の制御および特徴付け

Country Status (8)

Country Link
US (3) US20140082758A1 (enExample)
EP (1) EP2635110B1 (enExample)
JP (2) JP5986575B2 (enExample)
CN (2) CN106267236A (enExample)
AU (3) AU2011323197B2 (enExample)
CA (1) CA2816987C (enExample)
ES (1) ES2682962T3 (enExample)
WO (1) WO2012061741A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8926959B2 (en) 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US10052497B2 (en) 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US20070053996A1 (en) 2005-07-22 2007-03-08 Boyden Edward S Light-activated cation channel and uses thereof
WO2008086470A1 (en) 2007-01-10 2008-07-17 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
WO2008101128A1 (en) 2007-02-14 2008-08-21 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
WO2008106694A2 (en) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
US10035027B2 (en) 2007-10-31 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Device and method for ultrasonic neuromodulation via stereotactic frame based technique
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
SG189813A1 (en) 2008-04-23 2013-05-31 Univ Leland Stanford Junior Systems, methods and compositions for optical stimulation of target cells
JP5890176B2 (ja) 2008-05-29 2016-03-22 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー セカンドメッセンジャーを光制御するためのセルライン、システム、および方法
EP2303405A4 (en) 2008-06-17 2017-12-27 The Board of Trustees of the Leland Stanford Junior University Apparatus and methods for controlling cellular development
AU2009260029B2 (en) 2008-06-17 2016-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods, systems and devices for optical stimulation of target cells using an optical transmission element
US9101759B2 (en) 2008-07-08 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
JP5866332B2 (ja) 2010-03-17 2016-02-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 感光性イオンを通過させる分子
WO2012061681A1 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University. Control and characterization of memory function
EP3486253A1 (en) 2010-11-05 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
CA2816987C (en) * 2010-11-05 2018-09-18 The Board Of Trustees Of The Leland Stanford Junior University Control and characterization of psychotic states
US9992981B2 (en) 2010-11-05 2018-06-12 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of reward-related behaviors
CN106106368A (zh) 2010-11-05 2016-11-16 斯坦福大学托管董事会 光控cns功能障碍
CA2817175C (en) 2010-11-05 2019-09-24 The Board Of Trustees Of The Leland Stanford Junior University Upconversion of light using lanthanide-doped nanoparticles for use in optogenetic methods
CN103491770B (zh) 2010-11-05 2016-06-08 斯坦福大学托管董事会 稳定阶跃函数视蛋白及其使用方法
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
EP3524676A1 (en) 2011-12-16 2019-08-14 The Board of Trustees of The Leland Stanford Junior University Opsin polypeptides and methods of use thereof
ES2628006T3 (es) 2012-02-21 2017-08-01 Circuit Therapeutics, Inc. Composiciones para el tratamiento de trastornos neurogénicos del suelo pélvico
US10974064B2 (en) 2013-03-15 2021-04-13 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of behavioral state
US9636380B2 (en) 2013-03-15 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of inputs to the ventral tegmental area
WO2014179331A2 (en) 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Devices, systems and methods for optogenetic modulation of action potentials in target cells
CA2921221A1 (en) 2013-08-14 2015-02-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for controlling pain
EP3122761B1 (en) 2014-03-28 2019-03-06 The Board of Trustees of The Leland Stanford Junior University Engineered light-activated anion channel proteins and methods of use thereof
US9279797B2 (en) 2014-06-12 2016-03-08 Axion Biosystems, Inc. Multiwell microelectrode array with optical stimulation
WO2016209654A1 (en) 2015-06-22 2016-12-29 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture
WO2025041032A1 (en) * 2023-08-22 2025-02-27 Friedrich Miescher Institute For Biomedical Research Promoter for the specific expression of genes in layer 5 cells in mouse cortex
WO2025041033A1 (en) * 2023-08-22 2025-02-27 Friedrich Miescher Institute For Biomedical Research Promoter for the specific expression of genes in layer 5 pyramidal tract cells in mouse cortex
WO2025041034A1 (en) * 2023-08-22 2025-02-27 Friedrich Miescher Institute For Biomedical Research Promoter for the specific expression of genes in layer 5 cells in mouse cortex

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001263199B2 (en) * 2000-05-17 2004-09-16 Asterias Biotherapeutics, Inc. Neural progenitor cell populations
EP1573314B1 (en) * 2002-12-16 2008-07-23 Genentech, Inc. Transgenic mice expressing human cd20
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
US7521590B2 (en) * 2006-09-01 2009-04-21 Korea Institute Of Science And Technology Phospholipase C β1 (PLCβ1) knockout mice as a model system for testing schizophrenia drugs
NZ602416A (en) * 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
WO2011005978A2 (en) * 2009-07-08 2011-01-13 Duke University Methods of manipulating cell signaling
EP3486253A1 (en) * 2010-11-05 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
CN103491770B (zh) 2010-11-05 2016-06-08 斯坦福大学托管董事会 稳定阶跃函数视蛋白及其使用方法
CA2816987C (en) * 2010-11-05 2018-09-18 The Board Of Trustees Of The Leland Stanford Junior University Control and characterization of psychotic states

Also Published As

Publication number Publication date
US20210059230A1 (en) 2021-03-04
JP2013544091A (ja) 2013-12-12
US20160316732A1 (en) 2016-11-03
CA2816987C (en) 2018-09-18
CN106267236A (zh) 2017-01-04
AU2011323197A1 (en) 2013-05-09
WO2012061741A3 (en) 2013-08-08
US20140082758A1 (en) 2014-03-20
CN103339505A (zh) 2013-10-02
ES2682962T3 (es) 2018-09-24
EP2635110A2 (en) 2013-09-11
WO2012061741A2 (en) 2012-05-10
AU2016200948A1 (en) 2016-03-03
CN103339505B (zh) 2016-08-24
CA2816987A1 (en) 2012-05-10
AU2011323197B2 (en) 2015-11-19
JP2017029148A (ja) 2017-02-09
EP2635110B1 (en) 2018-05-09
EP2635110A4 (en) 2014-02-26
AU2018208657A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
JP5986575B2 (ja) 精神病状態の制御および特徴付け
JP6445602B2 (ja) 報酬関連行動の光遺伝学的制御
US10307609B2 (en) Compositions and methods for controlling pain
JP6549559B2 (ja) 標的細胞における活動電位の光遺伝学的調節のための装置、システム及び方法
JP6594854B2 (ja) 行動状態の光遺伝学的制御方法
US20140271479A1 (en) Optogenetic control of inputs to the ventral tegmental area
CN103491770A (zh) 稳定阶跃函数视蛋白及其使用方法
Krauss In vitro and in vivo advances in application of optogenetic techniques to non-human primates
Kolstad Development and assessment of gene therapies for inherited blinding diseases
Saunders Circuit interactions between the cortex and basal ganglia
Mantoan Neuronal Signalling Studied with Light-activated Ion Channels to Target Interneurons, Entrain Hippocampal Gamma Oscillations and Suppress Epileptiform Activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160805

R150 Certificate of patent or registration of utility model

Ref document number: 5986575

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees